Last reviewed · How we verify
FOSTAMATINIB DISODIUM
At a glance
| Generic name | FOSTAMATINIB DISODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2018 |
Approved indications
Common side effects
Key clinical trials
- Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults (PHASE2)
- Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
- Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (PHASE3)
- Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects (PHASE3)
- A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA (PHASE3)
- A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (PHASE3)
- A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) (PHASE2)
- A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOSTAMATINIB DISODIUM CI brief — competitive landscape report
- FOSTAMATINIB DISODIUM updates RSS · CI watch RSS